MilliporeSigma expands antibody-drug conjugate manufacturing

By The Science Advisory Board staff writers

September 9, 2020 -- MilliporeSigma is expanding its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) manufacturing capabilities with a $65 million investment at its Madison, WI, facility.

The investment will support large-scale manufacturing of compounds that have the potential to treat cancer. The expansion is expected to be complete by mid-2022 and will add approximately 50 full-time jobs starting in 2021.

MilliporeSigma is expanding its ADC manufacturing capabilities.
MilliporeSigma is expanding its ADC manufacturing capabilities. ADCs are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells, while preserving healthy ones. Image courtesy of MilliporeSigma.

The new 70,000-sq-ft commercial building will be a dedicated HPAPI manufacturing space designed to handle single-digit nanogram occupation exposure limit materials. The facility will incorporate containment areas to produce next-generation linker and payload materials for ADCs. The facility will add to the company's existing ADC manufacturing capabilities in St. Louis, MO.

MIT, MilliporeSigma create Pandemic Response CoLab
The Massachusetts Institute of Technology (MIT) has launched Pandemic Response CoLab with the goal of bringing together innovators from around the globe...
MilliporeSigma, Baylor partnering on COVID-19 vaccine
MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership...
Need for efficiency, COVID-19 vaccine spurs biomanufacturing in 2020
With the urgent need for COVID-19 therapies and vaccines, funding agencies have prioritized biomanufacturing; companies in turn are preparing to ramp...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter